An integrated pharmaceutical company with revenues in excess of US$2.5 billion and presence in 18 country sites across Asia, Australia, the Americas, Europe, and Africa.
An integrated pharmaceutical company with presence in 18 country sites across Asia, Australia, the Americas, Europe, and Africa had a mature ESG standing and required help to further drive its ESG agenda. With the support of Uniqus ESG experts, science-based targets developed for the client were approved for the second year. This created a platform for the implementation of robust energy-saving initiatives and identification of 20% potential for energy savings through 18 site audits. The improvements in performance led to enhanced ESG ratings across CDP and DJSI.